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Integrins are cell-surface receptors, which mediate cell-to-cell and cell-to-extracellular matrix adhesion. Besides playing an important
role in tumour angiogenesis, b3-integrin is also expressed in several types of epithelial cancer cells. It was the purpose of the present
study to evaluate the prognostic value of b3-integrin expression in patients with cervical cancer. Biopsies were taken from 82 patients
with squamous cell or adenocarcinomas of the uterine cervix who had undergone external-beam radiotherapy with or without
brachytherapy. These tissue samples were analysed immunohistochemically for the expression of b3-integrin. The impact of
immunoreactivity for b3-integrin on survival end points was assessed by univariate and multivariate analyses, and its correlation with
clinicopathological characteristics evaluated by crosstabulations. b3-integrin was expressed in 61% (50 of 82) of the patients. Kaplan–
Meier curves revealed local progression-free survival, distant metastasis-free survival and cause-specific survival to be significantly
shorter (P-values according to the log-rank test: 0.002, 0.04 and 0.01, respectively) in patients with b3-integrin expression. The
prognostic impact of this parameter was even higher than for other well-known prognostic parameters and remained statistically
significant in the multivariate analyses. b3-integrin, which is expressed in the majority of patients with advanced cervical cancer, has a
significant prognostic impact on outcome according to univariate and multivariate analyses.
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Tumour cells are heavily influenced by their microenvironment.
They derive important information not only from soluble factors,
such as hormones, cytokines and growth factors, but also via direct
interactions with neighbouring cells and extracellular matrix
molecules.
The integrins are a family of transmembrane cell-surface
receptors, which participate in cell-to-cell and cell-to-extracellular
matrix interactions. They consist of a- and b-subunits. The
cytoplasmic tails of the b-subunit contain two highly conserved
motifs (NPXY and NXXY), which play a major role in the
regulation of integrin-mediated functions (Dedhar and Hannigan,
1996). At least 20 different signalling proteins can associate with
activated integrin receptors (Miyamoto et al, 1995). These
cooperative interactions set in train signalling cascades, which
are involved in cell differentiation, adhesion, migration, invasion,
proliferation, angiogenesis and survival (for reviews, see Varner
and Cheresh, 1996; Dedhar, 1999; Brakebusch et al, 2002). And,
there is an increasing body of evidence indicating that integrins
mediate the development of metastases in certain organs (Pecheur
et al, 2002). Several of these signalling cascades involve ras or
phosphatidyl inositol 3-kinase, and have been demonstrated to
prevent apoptosis (for review, see Shain et al, 2000). Some of the
aforementioned biological events are at least partially invoked by
intercommunication between growth-factor receptors and integ-
rins (Miyamoto et al, 1996; Eliceiri and Cheresh, 2001). There is a
growing body of evidence indicating that integrins are involved in
drug resistance (for a review, see Shain et al, 2000).
avb3 is one of the most actively investigated members of the
integrin receptor family. It is overexpressed in blood vessels, and
together with the other known b-3 integrin, aIIbb3, is synthesised
by malignant epithelial cells. Comparative ELISA and immuno-
precipitation have revealed avb3 to be expressed at much higher
levels in human malignant cervical tumours than in nonmalignant
cervical tissue (Chattopadhyay and Chatterjee, 2001). The clinical
significance has been prospectively analysed in 111 patients with
melanomas of intermediate thickness. The analysis revealed the
expression of b3-integrins to be associated with a higher risk of
death (Hieken et al, 1996, 1999).
In the present study, we wished to ascertain whether the
expression of b3-integrins could serve as a prognostic marker for
survival in cervical cancers that had undergone radiotherapy. We
also wished to determine whether the expression of b3-integrins is
linked with that of p53, since the administration of avb3
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santagonists during angiogenesis is known to induce apoptosis, to
selectively activate the synthesis of p53 by endothelial cells and to
increase the expression of the p53-inducible cell-cycle inhibitor,
p21
WAF1/CIP1 (Stromblad et al, 1996).
PATIENTS AND METHODS
In all, 91 patients who had undergone radiotherapy with a curative
intent for squamous cell or adenocarcinomas of the cervix between
1990 and 1998 were eligible for this study. Individuals who had
received surgical treatment for the primary tumour or the regional
lymph nodes were not included. Biopsies from paraffin-embedded
tissue samples were obtained with the approval of the Regional
Board of the Medical Ethics Commission and with the informed
written consent of the patients. In nine cases, no biopsy material
was available, and these patients were excluded. Hence, 82
individuals qualified for inclusion in this study. In total, 73 of
these patients had advanced FIGO stages (IIb–IVa) and nine had
FIGO stages Ib–IIa. The latter nine patients were subjected to
radiotherapy owing to comorbidity, which rendered their condi-
tion inoperable.
The clinical characteristics of the patient cohort are summarised
in Table 1. Tumour staging was ascertained by clinical examina-
tion under anaesthesia, by chest X-radiography and by computer
tomography (CT) of the pelvis, which was replaced or supple-
mented by MRI in several patients. Suspicious radiological
findings respecting the size (41cm) and configuration of regional
lymph nodes were not routinely substantiated by a histopatholo-
gical analysis. However, borderline cases did undergo histopatho-
logical evaluation, and in seven of these positive lymph nodes were
revealed. Prior to radiotherapy, all patients underwent two- or
three-dimensional CT-based planning, simulator and portal-vision
imaging devices being used as controls. External-beam radio-
therapy (EBRT) was delivered via a 6- or 15-MV linear accelerator,
a median total dose of 56Gy (range: 31–67) being administered. A
four-field box technique was used to deliver daily fractions of 1.8
or 2Gy five times per week.
If the tumour regressed sufficiently after EBRT, then high-dose-
rate brachytherapy (BT) with 192-Ir was administered. A median
192-Ir dose of 17Gy, delivered in a median of four fractions, was
given to point A. In 21 of the 82 patients, BT could not be instigated
owing to the persistence of the tumoral mass and/or the destruction
of the cervix, which rendered intracavitary treatment impossible. In
these cases, a higher dose of EBRT was applied. The median total
dose delivered to point A was 69Gy. A total of 27 patients (33%)
underwent concomitant cisplatin-based chemotherapy.
Following the course of radiotherapy, patients underwent a
clinical examination and pelvic MRI or CT to define the response
to treatment. The follow-up included clinical examinations in our
department and/or by a gynaecologist. The mean follow-up time
was 41 months (range: 3–131 months).
Immunohistochemistry
b3-integrins: Sections (3mm thick) of paraffin-embedded biopsy
material were transferred to gelatinised microslides and air-dried
overnight at 371C. They were then dewaxed in xylene (three
changes), rehydrated in ethanol and rinsed twice in Tris-buffered
saline (TBS: 50mM Tris/HCl (pH 7.4) containing 100mM sodium
chloride). Endogenous peroxidase activity was suppressed by
treatment with 0.3% hydrogen peroxide (in TBS) for 10min.
Sections were then treated in a microwave oven (180W) for 15min
and treated with 1% casein ((Sigma 8654) in TBS) for 10min to
block unspecific binding. They were then incubated with the first
antibody: mouse monoclonal anti-b3-integrins ((MAB2008; Che-
micon International, Temecula, CA, USA) diluted 1:50 in TBS) for
15h at 41C. Subsequently, the sections were exposed to an affinity-
purified biotinylated second antibody ((anti-mouse EO 433; Dako,
Glostrup, Denmark) diluted 1:200 in TBS) for 45min at ambient
temperature, washed three times in TBS and then treated with the
avidin–biotin–horseradish peroxidase complex (P355, Dako,
Glostrup, Denmark) for a similar period at the same temperature.
The reaction product was visualised by exposing sections to 3-
amino-9-ethylcarbazole or to 3,3-diaminobenzidine (Sigma Che-
micals Company, St Louis, MI, USA). They were then mounted in
Aquatex (Merck, Darmstadt, Germany). Negative controls were
prepared using nonspecific mouse sera.
Initially, it was planned to evaluate the expression of b3-
integrins within tumoral endothelial cells as well as within the
epithelial ones. However, the endothelial cells seldom expressed
b3-integrins, probably because the biopsies were usually small and
therefore lacked activated capillaries characteristic for vascular
‘hot spots’ (Gasparini et al, 1998). Immunoreactivity for b3-
integrins within tumoral epithelial cells was graded semiquantita-
tively as follows:  , undetected or negligible (o1% of the tumoral
cells registering positive); þ, weak (1–10% of the tumoral cells
registering positive); and þþ, strong (410% of the tumour cells
Table 1 Bivariate correlations (Fisher’s exact test) between b3-integrin
expression and patient-, tumour- and therapy-related parameters
b3 expression
Parameter Total (%) Negative (%) Positive
a (%) P-value
Total 82 (100) 32 (39) 50 (61)
Median age (yrs)
o63 41 (50) 13 (32) 28 (68)
X63 41 (50) 19 (46) 22 (54) 0.26
FIGO stage
I/II 42 (51) 18 (43) 24 (57)
III/IV 40 (49) 14 (35) 26 (65) 0.50
Differentiation
b
Grade 1 3 (4)
Grade 2 40 (55) 16 (40) 24 (60)
Grade 3 30 (41) 12 (40) 18 (60) 1.00
Lymph-node metastasis
Yes 32 (39) 9 (28) 23 (72)
No 50 (61) 23 (46) 27 (54) 0.16
Histology
Adeno/-squamous 15 (18) 7 (47) 8 (53)
Squamous 67 (82) 25 (37) 42 (63) 0.57
P53 expression
b
Negative 54 (67) 21 (39) 33 (61)
Positive 26 (33) 10 (38) 16 (62) 1.00
Haemoglobin
b
oMedian 40 (49) 17 (42) 23 (58)
4Median 41 (51) 14 (34) 27 (66) 0.50
Median total dose (Gy)
p69 42 (51) 16 (38) 26 (62)
469 40 (49) 16 (40) 24 (60) 1.00
Radiotherapy
BT 1 (1)
EBRT+BT 60 (73) 25 (42) 35 (58)
EBRT 21 (26) 6 (29) 15 (71) 0.43
Chemotherapy
Yes 27 (33) 7 (26) 20 (74)
No 55 (67) 25 (45) 30 (55) 0.10
BT¼brachytherapy; EBRT¼external-beam radiotherapy.
aCombined group of
‘weak’ and ‘strong’ b3 expression.
bParameter was not available for all patients.
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sregistering positive). When more than one biopsy per patient was
available, the highest score was selected for further evaluation. The
assessment was performed at a final magnification of  200 in a
blinded manner and independently by two investigators (JH, VD).
Conflicting scores were resolved at a discussion microscope.
p53: Sections (3mm thick) of paraffin-embedded biopsy material
were treated as described for b3-integrins up to the end of the
incubation with 0.3% hydrogen peroxide. They were then bathed
in 0.01 M sodium citrate (pH 6.0), heated in a microwave oven
(180W) for 15min and exposed to 1% casein (in TBS) for 10min.
Sections were then incubated with the first antibody: mouse anti-
p53 ((DO-7. M 7001; DAKO, Glostrup, Denmark) diluted 1:200 in
TBS) for 15h at 41C. Exposure to the second antibody and
subsequent treatment accorded with the descriptions already given
for b3-integrins. Negative controls were similarly prepared using
nonspecific mouse sera. Sections were counterstained with
haematoxylin. If more than 10% of the tumour cells exhibited
intense nuclear staining, p53 was considered to have been
overexpressed. When more than one biopsy per patient was
available, the highest score was selected for further evaluation.
Sections were assessed microscopically as described for b3-
integrins.
Statistics
The bivariate analysis involving the expression of b3-integrins and
clinicopathological covariables was conducted using Fisher’s exact
test, the two-sided significance level being set at 5%.
For the survival analysis, three end points were used: local
progression-free survival (LPFS), distant metastasis-free survival
(DMFS) and cause-specific survival (CSS). Local progression
during or after therapy was the determining event for LPFS, and
death from the tumour (not from noncancer-related cause) for
CSS. LPFS, DMFS and CSS were investigated by univariate and
multivariate analyses (using the log-rank test and Cox’s model,
respectively). The qualifying criterion for inclusion in Cox’s
regression analysis was a P-value p0.1 in the univariate analysis.
A backward elimination procedure was then performed to
eliminate nonsignificant parameters (PX0.1). Survival curves were
plotted according to the Kaplan–Meier method, the log-rank test
being used to determine significant differences between these.
Statistical analyses were performed using the SPSS package
(Version 11.0; SPSS Inc., Chicago, IL, USA).
RESULTS
Expression of b3-integrins
In 32 patients (39%), b3-integrins were either not detected or
expressed at negligible levels. In the cases that manifested clear
evidence of immunoreactivity (n¼50; 61%), 31 (38%) exhibited
‘weak’ (þ) and 19 (23%) ‘strong’ (þþ) staining (Figure 1).
Bivariate correlations revealed no significant association between
the expression of b3-integrins and any clinicopathological para-
meter, including p53 expression. However, biopsies derived from
patients with clinically positive lymph nodes and from those who
had undergone chemotherapy were more prone to register positive
for b3-integrins. The crosstabulations are summarised in Table 1.
Univariate survival analysis
The Kaplan–Meier survival curves (Figure 2) revealed significantly
worse LPFS (P¼0.007) and CSS (P¼0.038), and a tendency for
impaired DMFS (P¼0.09) in patients expressing b3-integrins.
Those with ‘weak’ or ‘strong’ b3-integrin expression had a similar
outcome and were combined for further statistical analyses. These
disclosed patients with b3-integrins positivity to fare significantly
worse with respect to all end points (LPFS: P¼0.002; DMFS:
P¼0.036; and CSS: P¼0.011).
For LPFS, lymph-node status (P¼0.009), the pretreatment level
of haemoglobin (P¼0.03) and the implementation of BT
Figure 1 Graded semiquantitatively immunoreactivity for b3-integrins (brown colouration) within tumoral epithelial cells: undetected or negligible (A),
weak (B) and strong (C and D). Bar 50mm – see (D).
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s(P¼0.009) were also significant. FIGO stage and the histological
tumour type had a borderline impact (P¼0.09 and 0.07,
respectively). For DMFS and CSS, lymph-node status and
histological tumour type were significant. The results of the
univariate survival analysis are summarised in Table 2.
Multivariate survival analysis
Cox’s regression analysis confirmed b3-integrins positivity to have
an independent and significant bearing on outcome (LPFS:
RR¼6.81, P¼0.001; DMFS: RR¼3.99, P¼0.016; CSS: RR¼4.36,
P¼0.002). The histological subtype likewise had an impact on all
end-points (LPFS: RR¼3.47, P¼0.01; DMFS: RR¼4.25, P¼0.007;
CSS: RR¼4.52, P¼0.001). The pretreatment level of haemoglobin
was significant for LPFS (RR¼0.31, P¼0.005) and CSS
(RR¼0.45, P¼0.033). Nodal status was of borderline significance
for DMFS (P¼0.06) and CSS (P¼0.08). For LPFS, neither nodal
status nor FIGO stage was important. These findings are
summarised in Table 3.
DISCUSSION
Within the large integrin family, only two of the known a-subunits,
aIIb and av, can dimerise with b3, thereby yielding aIIbb3 and
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Figure 2 Local progression-free survival (A), DMFS (B) and CSS (C),
expressed as a function of ‘negative’, ‘weak’ or ‘strong’ immunoreactivity for
b3-integrins in our cohort of 82 patients with cervical cancer. P-values were
determined according to the log-rank test.
Table 2 Estimates of LPFS, DMFS and CSS 5 years after treatment,
determined according to the Kaplan–Meier method* and the univariate
analyses (log-rank test**) for various clinicopathological characteristics in
our cohort of 82 patients with cervical cancer
5yrs – LPFS* 5yrs – DMFS* 5yrs – CSS*
Parameter % P-value** % P-value** % P-value**
Age 0.53 0.60 0.80
oMedian 60786 5 795 1 79
4Median 69787 4 786 2 78
FIGO stage 0.09
a 0.80 0.25
I/II 72787 2 786 4 78
III/IV 54796 4 710 4679
Histology 0.07
a 0.012
a 0.016
a
Adeno/-squamous 48714 41715 34713
Squamous 68767 5 766 0 77
Differentiation 0.14 0.62 0.22
Grade 2 56796 4 710 4879
Grade 3 78787 4 796 5 79
Nodal status 0.009
a 0.004
a 0.002
a
Negative 76768 2 776 9 77
Positive 43710 47711 32710
Haemoglobin 0.03
a 0.89 0.09
a
oMedian 51710 66711 45710
4Median 73776 9 786 1 78
Chemotherapy 0.95 0.56 0.88
Yes 65710 65710 55710
No 64777 3 775 6 78
Brachytherapy 0.009
a 0.98 0.16
Yes 69766 8 775 8 77
No 45713 72713 45713
Total dose 0.47 0.81 0.43
oMedian 61797 1 795 5 79
4Median 67786 7 785 7 79
P53 expression 0.20 0.75 0.20
Negative 71766 9 775 8 78
Positive 51712 71710 51711
b3 expression 0.007 0.09 0.038
Negative 85778 5 777 8 78
Weak positive 46710 67710 44710
Strong positive 57712 50713 39712
b3 expression 0.002
a 0.036
a 0.011
a
Negative 85778 5 777 8 78
Positive 51785 7 794 1 78
LPFS¼local progression-free survival; DMFS¼distant metastasis-free survival;
CSS¼cause-specific survival.
aMarked parameters were included in multivariate
analysis.
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savb3. Hitherto, aIIbb3 was believed to be expressed only within
cells of the megakaryocyte lineage (Hynes, 1992). However, recent
findings have revealed this integrin to be synthesised by a variety
of tumour cells at different histological sites, such as blood, the
lung, liver, kidney, colon, bladder, breast, prostate and cervix
(Chen et al, 1997).
The integrin avb3, also known as the vitronectin receptor, has
been implicated in the pathophysiology of malignant tumours. It
plays an important role in angiogenesis, particularly via its
expression in ‘activated’ endothelial cells (Brooks et al, 1994).
However, the exact mechanisms underlying pro- and antiangio-
genic signalling remain obscure (for a review, see Hodivala-Dilke
et al, 2003). More recently, tumour cells have also been recognised
to synthesise avb3 (Chen et al, 1997). A possible link between its
expression therein and tumour progression and/or invasiveness
has been suggested for melanomas, glioblastomas and cancers of
the breast, stomach and cervix (Albelda et al, 1990; Pignatelli et al,
1992; Gingras et al, 1995; Kawahara et al, 1995; Chattopadhyay and
Chatterjee, 2001).
In a few studies, a significant association has been demonstrated
to exist between patient survival and the expression of avb3
by vascular ‘hot spots’, which served as a marker for angioge-
nesis (Gasparini et al, 1998; Vonlaufen et al, 2001). No data
respecting a possible link between aIIbb3 expression and out-
come have been forthcoming. In human melanomas, both the
b3-integrins are likely to be involved in tumour progression
(Trikha et al, 2002). In a study involving 111 patients with
primary malignant melanomas, 71 (64%) were shown to express
b3-integrins (Hieken et al, 1999), and these individuals were more
likely to develop lung metastasis and to die of their disease (45%
(32 of 71 patients)) than were those with b3-integrin-negative
tumours (8% (three of 40 patients)), a finding that was highly
significant (Po0.0001).
We here report for the first time that likewise in patients (most
of them) with advanced stages of cervical cancer, the expression of
b3-integrins is associated with an impaired outcome, irrespective
of the level of immunoreactivity. Indeed, the significance of this
factor was higher than for other prognostic parameters. Lymph-
node metastasis, a very potent parameter in the univariate analysis,
failed to attain significance for LPFS in Cox’s regression
model, which is contrary to previous findings of our group (Burri
et al, 2003). There exist some differences in patient number and
in the follow-up time, but these factors alone cannot account
for the present results. The inclusion of b3-integrins as a new
parameter in the multivariate analysis most likely diminished
the importance of lymph-node status. In the present investiga-
tion, overall survival was replaced by CSS, since several patients
had a high comorbidity.
Integrin positivity was related to both local and distant failure
and might be more an indicator for a bad prognosis in general
than a predictor for radiation response. Although a direct action
of specific integrin inhibitors on tumour growth is foreseeable, a
combined approach, involving integrin blockage and cytotoxic
therapy, might also have a sensitising effect. In conjunction
with radiotherapy, the most likely benefit to be derived from
treatment with integrin inhibitors is an antiangiogenic effect.
Indeed, administration of an avb3 antibody/antagonist has
been shown to result in the apoptosis of angiogenic but not
of quiescent vascular cells (Brooks et al, 1994). And, function-
blocking antibodies against avb3 have been demonstrated to
inhibit the VEGF-stimulated phosphorylation of VEGFR-2
and activation of the regulatory subunit of phosphatidyl isonitol
3-kinase (Soldi et al, 1999).
Several endogenous angiogenesis inhibitors may partially exert
their antiproliferative effects via avb3. This has been demonstrated
for endostatin (Rehn et al, 2001), angiostatin (Tarui et al, 2001),
thrombospondin-1 (for a review, see Bornstein, 2001) and
tumstatin (Maeshima et al, 2000). Indeed, when molecules such
as angiostatin (Gorski et al, 1998; Mauceri et al, 1998), endostatin
(Hanna et al, 2000) or neutralising anti-human VEGF165 antibodies
(Gorski et al, 1999; Lee et al, 2000) are administered together with
ionising radiation, the cytotoxic effects of the latter upon
endothelial cells are potentiated in vivo, resulting in an enhanced
antitumoral effect. Likewise, when radiotherapy is combined with
the administration either of antibodies against VEGFR-2 or of the
antiangiogenic compound TNP-470, the growth-retarding effects
of radiation is potentiated (Teicher et al, 1996; Lund et al, 2000;
Hess et al, 2001; Kozin et al, 2001).
As far as we are aware, only one in vitro study has demonstrated
a synergic, retarding effect of radiotherapy and avb3 blockage on
tumour cell growth (Abdollahi et al, 2003).
And as yet, there is no evidence indicating that a blockage of
b3-integrin expression results in radiosensitisation. Since integrin-
mediated cell signalling is implicated in cell migration, invasion
and survival, targeting this event could be as important as the
direct inhibition of angiogenesis.
In conclusion, there was a significant relationship between
b3-integrins expression and survival/local control in our hetero-
geneous group of patients with cervical cancer treated by
radiotherapy. It seems worth investigating further the prog-
nostic impact in a larger cohort of patients as it might have
long-term implications in selecting patients who will do badly
with standard treatment and might benefit from integrin
modulation therapy.
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Table 3 Multivariate analysis for LPFS, DMFS and CSS according to
Cox’s regression model in our cohort of 82 patients with cervical cancer
LPFS DMFS CSS
P-value P-value P-value
RR (95% CI) RR (95% CI) RR (95% CI)
FIGO stage 0.39 — —
III/IV vs I/II 1.47 (0.61–3.57)
Histology 0.01 0.007 0.001
Adeno/-
squamous vs
squamous
3.47 (1.31–9.17) 4.25 (1.50–12.04) 4.52 (1.83–11.18)
Nodal status 0.49 0.06 0.08
Positive vs
negative
1.34 (0.59–3.03) 2.32 (0.94–5.76) 1.87 (0.92–3.81)
Haemoglobin 0.005 0.033
4Median vs
omedian
0.31 (0.14–0.71) 0.45 (0.22–0.94)
Brachytherapy 0.09 — —
Yes vs no 0.49 (0.21–1.12)
b3 expression 0.001 0.016 0.002
Positive vs
negative
6.81 (2.21–21.00) 3.99 (1.29–12.35) 4.36 (1.73–11.00)
LPFS¼local progression-free survival; DMFS¼distant metastasis-free survival;
CSS¼cause-specific survival; RR¼risk ratio; CI¼confidence interval.
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